List view / Grid view
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…
An epigenetic pathway is mediated by a certain protein that could potentially reverse vascular remodelling in pulmonary hypertension.
A living material resembling sputum from CF patients can grow biofilms, enabling scientists to assess the effectiveness of antimicrobials.
Researchers have developed a new method to study protein clumps that occur in many difficult-to-treat diseases.
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
Researchers often encounter common problems during protein sample preparation which can compromise the quality and quantity of protein obtained. Explore our solutions to these common challenges, including sample handling, storage and preparation method issues.
Crosslinking damage to single stranded RNA, caused by aldehydes, is repaired by newly discovered mechanism involving ribosomes.
17 November 2023 | By
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
iPS-cell-derived microglia in brain organoids have enabled scientists to understand early brain development and microglia-associated disease.
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of…
The partial remission phase of type 1 diabetes, in which residual β-cells recover insulin production, offers new hope for therapeutic action.
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
